Luye Pharma Group Ltd. (2186.HK)
HKD 2.17
(-2.25%)
HKD 2.17
(-2.25%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 2.07 Billion CNY | 0.45% |
| 2022 | 1.81 Billion CNY | 94.67% |
| 2021 | 906.88 Million CNY | -49.79% |
| 2020 | 1.87 Billion CNY | -20.65% |
| 2019 | 2.38 Billion CNY | 25.13% |
| 2018 | 1.96 Billion CNY | 43.72% |
| 2017 | 1.35 Billion CNY | 21.42% |
| 2016 | 1.14 Billion CNY | 16.58% |
| 2015 | 1.02 Billion CNY | 9.79% |
| 2014 | 875.47 Million CNY | 69.09% |
| 2013 | 507.52 Million CNY | 45.56% |
| 2012 | 353.51 Million CNY | 17.95% |
| 2011 | 299.71 Million CNY | 8.22% |
| 2010 | 276.95 Million CNY | 25.35% |
| 2009 | 220.95 Million CNY | 127.8% |
| 2008 | 96.99 Million CNY | -17.93% |
| 2007 | 118.18 Million CNY | 23.48% |
| 2006 | 95.71 Million CNY | -7.17% |
| 2005 | 103.1 Million CNY | 10.77% |
| 2004 | 93.08 Million CNY | 36.32% |
| 2003 | 68.28 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 469.73 Million CNY | -8.67% |
| 2024 Q2 | 469.73 Million CNY | 0.0% |
| 2023 Q4 | 514.31 Million CNY | 0.0% |
| 2023 FY | - CNY | 0.45% |
| 2023 Q1 | 262.14 Million CNY | -21.31% |
| 2023 Q2 | 262.14 Million CNY | 0.0% |
| 2023 Q3 | 514.31 Million CNY | 96.2% |
| 2022 Q2 | 379.67 Million CNY | 0.0% |
| 2022 Q3 | 333.12 Million CNY | -12.26% |
| 2022 Q4 | 333.12 Million CNY | 0.0% |
| 2022 FY | - CNY | 94.67% |
| 2022 Q1 | 379.67 Million CNY | 492.68% |
| 2021 Q2 | 389.37 Million CNY | 0.0% |
| 2021 Q3 | 64.06 Million CNY | -83.55% |
| 2021 FY | - CNY | -49.79% |
| 2021 Q1 | 389.37 Million CNY | 63.11% |
| 2021 Q4 | 64.06 Million CNY | 0.0% |
| 2020 Q3 | 238.71 Million CNY | -51.76% |
| 2020 FY | - CNY | -20.65% |
| 2020 Q2 | 494.86 Million CNY | 0.0% |
| 2020 Q1 | 494.86 Million CNY | -0.97% |
| 2020 Q4 | 238.71 Million CNY | 0.0% |
| 2019 Q3 | 499.73 Million CNY | -2.32% |
| 2019 FY | - CNY | 25.13% |
| 2019 Q4 | 499.73 Million CNY | 0.0% |
| 2019 Q1 | 511.58 Million CNY | 5.07% |
| 2019 Q2 | 511.58 Million CNY | 0.0% |
| 2018 Q1 | 379.27 Million CNY | 11.13% |
| 2018 Q3 | 486.89 Million CNY | 28.37% |
| 2018 Q4 | 486.89 Million CNY | 0.0% |
| 2018 FY | - CNY | 43.72% |
| 2018 Q2 | 379.27 Million CNY | 0.0% |
| 2017 Q4 | 341.28 Million CNY | 0.0% |
| 2017 Q3 | 341.28 Million CNY | 34.01% |
| 2017 Q2 | 254.67 Million CNY | 0.0% |
| 2017 Q1 | 254.67 Million CNY | 20.11% |
| 2017 FY | - CNY | 21.42% |
| 2016 Q3 | 212.04 Million CNY | -16.32% |
| 2016 FY | - CNY | 16.58% |
| 2016 Q4 | 212.04 Million CNY | 0.0% |
| 2016 Q2 | 253.39 Million CNY | 0.0% |
| 2016 Q1 | 253.39 Million CNY | 23.16% |
| 2015 Q2 | 231.12 Million CNY | 0.0% |
| 2015 Q3 | 205.75 Million CNY | -10.98% |
| 2015 Q4 | 205.75 Million CNY | 0.0% |
| 2015 Q1 | 231.12 Million CNY | 9.42% |
| 2015 FY | - CNY | 9.79% |
| 2014 Q2 | 192.78 Million CNY | 0.0% |
| 2014 Q4 | 211.22 Million CNY | 0.0% |
| 2014 FY | - CNY | 69.09% |
| 2014 Q1 | 192.78 Million CNY | 52.71% |
| 2014 Q3 | 211.22 Million CNY | 9.57% |
| 2013 Q1 | 109.13 Million CNY | 0.0% |
| 2013 Q3 | 126.24 Million CNY | 15.68% |
| 2013 FY | - CNY | 45.56% |
| 2013 Q4 | 126.24 Million CNY | 0.0% |
| 2013 Q2 | 109.13 Million CNY | 0.0% |
| 2012 FY | - CNY | 17.95% |
| 2012 Q2 | 88.06 Million CNY | -3.23% |
| 2012 Q1 | 91 Million CNY | 24.44% |
| 2011 Q2 | 68.07 Million CNY | -8.14% |
| 2011 Q1 | 74.1 Million CNY | 66.68% |
| 2011 FY | - CNY | 8.22% |
| 2011 Q4 | 73.13 Million CNY | -13.35% |
| 2011 Q3 | 84.39 Million CNY | 23.97% |
| 2010 FY | - CNY | 25.35% |
| 2010 Q1 | 76 Million CNY | 43.32% |
| 2010 Q3 | 69.73 Million CNY | -19.62% |
| 2010 Q4 | 44.46 Million CNY | -36.24% |
| 2010 Q2 | 86.75 Million CNY | 14.14% |
| 2009 Q1 | 48.3 Million CNY | 0.0% |
| 2009 Q2 | 58.68 Million CNY | 21.49% |
| 2009 Q4 | 53.03 Million CNY | -12.96% |
| 2009 FY | - CNY | 127.8% |
| 2009 Q3 | 60.92 Million CNY | 3.81% |
| 2008 FY | - CNY | -17.93% |
| 2007 FY | - CNY | 23.48% |
| 2006 FY | - CNY | -7.17% |
| 2005 FY | - CNY | 10.77% |
| 2004 FY | - CNY | 36.32% |
| 2003 FY | - CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| CSPC Pharmaceutical Group Limited | 8.53 Billion HKD | 75.654% |